Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...

Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

New long-term data of the investigational therapy icotrokinra show that it is able to achieve site-specific clear or almost clear skin in patients with plaque psoriasis, according to results of the ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI 100, reflecting 100% improvement on the Psoriasis Area and Severity Index, ...

Whether misidentified as a skin problem or hygiene one, psoriasis is an intricate autoimmune condition that deserves more ...